New insider activity at Chemed ( (CHE) ) has taken place on May 29, 2026.

Memorial Day Sale – Claim 70% Off TipRanks

• Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
• Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Director George Walsh has recently cashed out a portion of his holdings in Chemed, selling 500 shares of the company’s stock in a transaction valued at $218,915. This insider sale highlights a notable move by a member of Chemed’s board, as the trade converts a significant block of his equity stake into cash while providing investors with a clear, disclosed record of his latest activity in the stock.

Recent Updates on CHE stock

Chemed’s stock reacted to its upbeat Q1 earnings call, where management raised 2026 revenue and EPS guidance mainly on stronger hospice trends at VITAS, including faster admissions growth, resilient margins, and a larger Florida Medicare cap cushion that eased prior regulatory concerns. Offsetting this, analysts noted ongoing margin pressure and higher marketing spend at Roto-Rooter, plus weather and pricing headwinds, leading to more cautious views even as overall earnings power improved.

Spark’s Take on CHE Stock

According to Spark, TipRanks’ AI Analyst, CHE is a Outperform.

The score is supported primarily by strong financial performance (healthy margins, low leverage, and strong free cash flow) and a generally positive earnings outlook led by VITAS and raised guidance. Technicals indicate an uptrend but are overbought, while valuation is reasonable but not cheap given the low dividend yield; governance sentiment is a modest drag due to the say-on-pay rejection.

To see Spark’s full report on CHE stock, click here.

More about Chemed

YTD Price Performance: 3.08%

Average Trading Volume: 261,253

Technical Sentiment Signal: Hold

Current Market Cap: $5.83B